Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...

MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail Loughborough, England, May 17, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and...

MySugarWatch Launches Physician-Focused Ads in MIMS As Part of Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor Loughborough, England, May 03, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and...

Nemaura Medical Wins Innovation Awards Loughborough, England, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...